Key Highlights

  • hVIVO plc (LSE:HVO) shows a Dividend Yield of 3.81%, a backward-looking figure based on past payments by the FTSE AIM All-Share constituent.
  • No Interim Dividend was declared with the results for the six months to 30 June 2026.
  • First-half Revenue fell to £16.3 million from £24.2 million, with an adjusted EBITDA loss of £4.5 million.
  • The weighted contracted orderbook more than doubled to £65 million, and the group orderbook reached a record £72 million including CRS Berlin.
  • Cash stood at £13.0 million at 30 June 2026, down from £14.3 million at the end of 2025.

A Headline Yield That Needs Context

hVIVO plc (LSE:HVO), the London-based clinical development partner best known as the world leader in human challenge trials, appears on dividend screens with a yield of 3.81%. For income investors, however, that number needs careful interpretation. It reflects dividends paid in the past rather than a payout the company is currently committing to, and the latest results confirm that no interim dividend has been declared for 2026.

That makes LSE:HVO a very different proposition from most stocks in the 2% to 4% yield bracket. The key question is not whether the current payout is covered, but whether and when the board will be in a position to resume distributions.

H1 2026 Results: A Weak First Half by Design

On 15 September 2026, hVIVO reported interim results for the six months ended 30 June 2026. Revenue dropped to £16.3 million from £24.2 million a year earlier, reflecting what management described as the second-half weighting it had guided at the start of the year. The adjusted EBITDA loss widened to £4.5 million from £3.0 million.

Chief Executive Yamin "Mo" Khan said the first half saw a clear improvement in commercial momentum. The company expects second-half revenue to be roughly double the first-half figure, giving full-year 2026 revenue of around £47 million, broadly similar to the £46.77 million reported for 2025. Some projects have been deferred into 2027 and 2028, which affected the original 2026 trajectory. Management expects positive adjusted EBITDA in the second half but a low single-digit adjusted EBITDA loss for the full year.

Orderbook Growth and the CRS Berlin Acquisition

The most encouraging element of the results was the orderbook. The weighted contracted orderbook more than doubled to £65 million at 30 June 2026 from £30 million at the end of 2025. Including CRS Berlin, which hVIVO acquired to expand its clinical platform and addressable market, the record group orderbook stood at £72 million. Management says this positions the group for significant growth in 2027.

CRS Berlin adds early-phase clinical capacity in Germany, broadening hVIVO beyond challenge studies into standalone client trials.

Dividend History

hVIVO paid modest dividends in recent years as it delivered profitable growth after its turnaround. In June 2025, for example, it paid a final dividend of 0.20p per share, costing around £1.4 million. Since then, trading has weakened. For 2025, the group reported a net loss of roughly £6 million, and Operating Cash Flow was negative. With no interim dividend declared for 2026, the trailing 3.81% yield is likely to fade as past payments drop out of the calculation.

Cash Flow and Balance Sheet

Cash fell to £13.0 million at 30 June 2026 from £14.3 million at the end of 2025, although management highlighted positive Working Capital inflows from recent contract wins. A year earlier, cash had been £23.3 million, so the Balance Sheet has absorbed a period of losses and investment, including the Acquisition of CRS Berlin. Preserving cash while the Business returns to profitability is a sensible priority, and it explains why the board has not declared an interim payment.

Leadership Changes

Alongside the results, hVIVO announced that Chief Financial Officer Stephen Pinkerton would retire at the end of September after ten years with the company. Non-executive director Richard Cotton has stepped in as interim CFO while the search for a permanent successor concludes. Changes in finance Leadership during a recovery phase are worth monitoring, although the company said it was in the final stages of selecting a new CFO.

Market Reaction and Sentiment

Shares fell after the results, with commentary across UK small-cap news services focusing on the revenue drop, the wider EBITDA loss and the CFO departure. With a Market Capitalisation of around £40 million, LSE:HVO is now a micro-cap. On investor forums and social platforms, discussion has centred on whether the record orderbook can translate into a sharp recovery in 2027 and whether dividends could return once profitability is restored.

Risks for Income Investors

The main risks are execution on the second-half revenue ramp, further project deferrals by pharmaceutical and biotech clients, and integration of CRS Berlin. Funding conditions across the biotech sector influence client spending on early-phase trials. Any shortfall against the £47 million revenue target would increase pressure on cash and push back the timing of any dividend resumption.

Verdict: Is the 3.81% Yield Sustainable?

For hVIVO plc (LSE:HVO), the 3.81% yield is not sustainable in its current form, because no interim dividend has been declared and the group is loss-making at the adjusted EBITDA level for 2026. However, the record orderbook and expected return to positive EBITDA in the second half give the business a path back to profitability. Income investors should treat LSE:HVO as a recovery play rather than a dividend stock until the board signals a return to regular payouts.